

SENEXTA

THERAPEUTICS

SeneXta at glance

Funded 2008

Business

Biopharmaceutical Company

Therapeutic Focus

Central Nervous System

Lead Product

SNX-001 for Alzheimer's Disease

Website

www.senexta.com

Headquarters

Lugano, Switzerland

R&D

University of Texas at El Paso (UTEP)

EXECUTIVE MANAGEMENT

Dr. Enrico Braglia, CEO & Founder
Dr. Federica Pericle, COO & Founder

SENEXTA TEAM

Dr. Donald Moss, Inventor, UTEP
Prof. R. Fariello, Clinical Expert
Dr. Igor Almeida, Analytical, UTEP
Dr. Robert Kirken, R&D, UTEP
Dr. Patricia Berlanga, Clinical Expert
Ms. Cynthia Molina, Regulatory

SENEXTA COLLABORATORS

SAFC, Ltd., API Manufacturing
Alpex Pharma, DP Manufacturing
Stillmeadow, Preclinical & Toxicology
Ricerca, Safety Pharmacology
Scope International, Clinical CRO
Clinrex GmbH, Clinical Coordinator
FGK GmbH, EU Legal Representative

COMPANY CONTACT

SeneXta Therapeutics SA
Via Cantonale, 1
6900 Lugano
Switzerland

Phone: +41(0)91 9124 24 00
Fax: +41(0)91 924 24 02
E-mail: info@senexta.com

Profile

SeneXta Therapeutics is a Swiss based biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders including Alzheimer's disease (AD), cognitive impairment secondary to ischemia, and other central nervous system (CNS) disorders. SeneXta currently has two programs in preclinical stage and one in clinical testing with SNX-001. The company is also broadening its product pipeline through licensing and acquisition. SeneXta uses a virtual development model focusing on products with clinical data and relatively lower overall risk.

Pipeline

Research			Pre-clinical Development	Clinical Development	
Exploratory	Hit to Lead	Optimization	IND enabling	Phase I	Phase II
SNX-001 Alzheimer's Disease				Q4 09	
SNX-001 New Formulation				Q1 09	
SNX-001 Post Stroke Cognitive Impairment				Q1 10	
SNX-002 TBD		Q1 10			

SNX-001

SNX-001, a patented selective novel inhibitor of acetylcholinesterase (AChE), being developed for the treatment of Alzheimer's disease (AD) and Post Stroke Cognitive Impairment. The basic science of SNX-001-induced AChE inhibition is fundamentally different from that of the short-acting AChE inhibitors that are available for the treatment of AD. SNX-001 produces long-acting AChE inhibition which improves its CNS-selectivity and reduces the peripheral toxicity (nausea, vomiting, and diarrhea) that limits the utility of short acting inhibitors. A previous exploratory, double-blind, placebo-controlled, cross-over study of SNX-01 in the treatment of AD demonstrated a clinically significant mean of six point improvement on the ADAS-Cog. SeneXta has completed the manufacturing and toxicology package for SNX-001 under GMP and GLP requirements. The company has submitted an IND and IMPD to evaluate the safety of SNX-01 in a new phase I clinical trial and has obtained approval in US (FDA) and Europe (Bfarm). SNX-001 is actually in human dosing double-blind placebo controlled phase I study in Germany.

SNX-001 Development Plan

- GLP toxicology studies – completed
- GLP safety pharmacology - completed
- GMP- Active Pharmaceutical Ingredient synthesized and validation – completed
- GMP - Drug Product manufacturing and validation- completed
- Investigational New Drug Application (IND and IMPD) – completed & approved
- Clinical Phase I dosing - ongoing
- SNX-001 new formulation - ongoing
- Phase II studies planning for 4Q 10 initiation – ongoing

www.senexta.com